emodepside (BAY 44-4400) / Bayer - LARVOL DELTA

EMOTI: Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita (clinicaltrials.gov) - P2 | N=100 | Not yet recruiting | Sponsor: Jennifer Keiser | Trial completion date: Sep 2026 ➔ Feb 2027 | Initiation date: May 2026 ➔ Nov 2026 | Trial primary completion date: Sep 2026 ➔ Jan 2027

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease

TREMO-Pemba: Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections (clinicaltrials.gov) - P3 | N=315 | Active, not recruiting | Sponsor: Swiss Tropical & Public Health Institute | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Infectious Disease

Recent advances in Strongyloides screening, diagnostics, therapeutics, and management. (PubMed, Curr Opin Infect Dis) - "Serologic and molecular tools are improving screening and diagnosis, and moxidectin and emodepside may broaden treatment options, but data in severe disease and special populations remain limited. Priorities include harmonized screening algorithms and prospective studies in high-risk groups."

Journal

Deep Learning-Driven Anticancer Drug Discovery: Emodepside as a Potential Therapeutic Candidate for Triple-Negative Breast Cancer. (PubMed, J Chem Inf Model) - "This study demonstrates the viability of our deep learning models to discover structurally novel anticancer agents that are distinct from conventional drugs, thereby expanding the therapeutic arsenal for TNBC patients. Emodepside emerges as a promising TNBC therapeutic candidate, with a possible mechanism of promoting TNBC cell apoptosis via NAMPT inhibition."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • NAMPT

TREMO-Pemba: Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections (clinicaltrials.gov) - P3 | N=315 | Enrolling by invitation | Sponsor: Swiss Tropical & Public Health Institute | Trial completion date: Jul 2026 ➔ Oct 2026

Trial completion date • Infectious Disease

EMOTI: Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita (clinicaltrials.gov) - P2 | N=100 | Not yet recruiting | Sponsor: Jennifer Keiser | Trial completion date: May 2026 ➔ Sep 2026 | Initiation date: Jan 2026 ➔ May 2026 | Trial primary completion date: May 2026 ➔ Sep 2026

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease

American Association of Veterinary Parasitologists Hookworm Task Force review on best practices for diagnosis and treatment of multidrug-resistant hookworms. (PubMed, J Am Vet Med Assoc) - "In the past few years, multiple anthelmintic drug resistance to fenbendazole, moxidectin, and pyrantel pamoate has been documented in A caninum in the US, and cases of drug-resistant canine hookworms are increasingly being reported in the US and Canada...In response to this concern, the American Association of Veterinary Parasitologists established a Hookworm Task Force in 2021, and this paper is a result of the work of that task force. Here we provide guidance on best practices for diagnosis, treatment, and management of drug-resistant hookworm cases and summarize relevant studies to help veterinarians understand what is known about the biology, prevalence, and epidemiology of these parasites."

Journal • Hematological Disorders • Infectious Disease

TREMO-Siargao: Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections (clinicaltrials.gov) - P3 | N=315 | Not yet recruiting | Sponsor: Swiss Tropical & Public Health Institute | Trial completion date: Dec 2026 ➔ Aug 2027 | Trial primary completion date: Sep 2026 ➔ Apr 2027

Trial completion date • Trial primary completion date • Infectious Disease

Evolution of Ivermectin Resistance in the Nematode Model Caenorhabditis elegans: Critical Influence of Population Size and Altered Emodepside Efficacy. (PubMed, Evol Appl) - "Evolution of ivermectin resistance led to reduced efficacy of the structurally related anthelmintic moxidectin, as anticipated, as well as reduced efficacy of the structurally unrelated anthelmintic emodepside, which has a distinct mode of action. In contrast, albendazole, levamisole, and monepantel efficacy were not influenced by the evolution of ivermectin resistance. We conclude that combining computational modeling with in vitro evolution experiments to test specific aspects of evolution directly represents a promising approach to guide the development of novel treatment strategies to anticipate and mitigate resistance evolution in parasitic nematodes."

Journal

A study to compare how well a single dose of a new medicine (emodepside) works in teenagers and adults with infections caused by worms in the soil, comparing it with the standard treatment (repeated doses of mebendazole) (clinicaltrialsregister.eu) - P3 | N=315 | Sponsor: Swiss Tropical and Public Health Institute

New P3 trial • Gastroenterology • Gastrointestinal Disorder • Infectious Disease

Current issues in heartworm chemotherapy. (PubMed, Parasit Vectors) - "It is perhaps unlikely that such studies will be undertaken, given the lack of economic motivation. Nonetheless, a review of the relevant literature leads to the conclusion that the status of heartworm infection in a dog bearing an apparently MADR hookworm infection be determined before starting treatment with emodepside, with caution exercised should it ensue."

Journal • Review • Infectious Disease

Efficacy evaluation of a new oral chewable tablet containing fluralaner, moxidectin, and pyrantel (BRAVECTO® TriUNO) against hookworm and Toxascaris leonina infections in a non-terminal study design in dogs. (PubMed, Parasit Vectors) - "A single, orally administered dose of this chewable tablet formulation is effective in treating canine infections with adult hookworms (U. stenocephala, A. caninum) and T. leonina. Non-terminal studies present a valid means of determining the efficacy of anthelmintic treatments for these canine intestinal parasites."

Journal • Infectious Disease

Topically administered macrocyclic lactone products, including eprinomectin, demonstrate comparable neurological safety in cats based on pharmacovigilance data. (PubMed, J Am Vet Med Assoc) - "The openFDA and EudraVigilance Veterinary Data Warehouse databases were queried for neurological AEs cumulatively reported through December 31, 2024, for marketed parasiticide products containing MLs (eprinomectin, selamectin, moxidectin) and emodepside for topical administration to cats. An evaluation of pharmacovigilance data from 2 different sources revealed no evidence of greater proportional reporting for neurological AEs specific to the use of eprinomectin-containing products in cats than for other MLs or emodepside. These findings supported the conclusion that ML-containing products (including eprinomectin-containing products) and emodepside are comparable in the frequencies and types of neurological AEs associated with feline topical parasiticide products described as substrates for P-glycoprotein transporters."

Adverse events • Journal • Ataxia • CNS Disorders • Epilepsy • Movement Disorders

TREMO-Pemba: Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections (clinicaltrials.gov) - P3 | N=315 | Enrolling by invitation | Sponsor: Swiss Tropical & Public Health Institute | Not yet recruiting ➔ Enrolling by invitation | Trial completion date: Apr 2026 ➔ Jul 2026

Enrollment open • Trial completion date • Infectious Disease

TREMO-Siargao: Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections (clinicaltrials.gov) - P3 | N=315 | Not yet recruiting | Sponsor: Swiss Tropical & Public Health Institute | Trial completion date: Sep 2026 ➔ Dec 2026 | Initiation date: Jan 2026 ➔ Apr 2026 | Trial primary completion date: Jun 2026 ➔ Sep 2026

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease

Can an absorptive sink improve the predictivity of biomimetic two-stage dissolution testing: Comparative IVIVC of various formulations of the poorly soluble drug emodepside. (PubMed, J Pharm Sci) - "While apparent dissolution yielded poor IVIVC, both molecular dissolution and dissolution-permeation yielded good and comparable IVIVCs. Finally, a refined mechanistic understanding is derived from the aforementioned dissolution and dissolution-permeation data to explain the observed differences."

Journal

Effects of emodepside on single-channel properties of Onchocerca volvulus SLO-1A (BK) potassium channels. (PubMed, Parasit Vectors) - "This study successfully expressed Ovo-SLO-1A in HEK293 cells, measured the conductance of the main open-state, and detected the presence of subconductance states and flickering openings. The increased amplitudes of the single-channel currents, open burst times, and open probabilities provides insights into the complex kinetics by which emodepside increases Slo-1K currents and illustrates the dynamic actions of emodepside on Ovo-SLO-1A."

Journal • Infectious Disease • Ophthalmology

EMOTI: Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita (clinicaltrials.gov) - P2 | N=100 | Not yet recruiting | Sponsor: Jennifer Keiser

New P2 trial • Infectious Disease

Antiparasitic agent emodepside exerts cytotoxicity in human corneal stromal cells by blocking the interaction between mini-chromosome maintenance 6 protein (MCM6) and chromatin licensing and DNA replication factor 1 (CDT1). (PubMed, Toxicology) - "Moreover, emodepside-induced cell cycle arrest in HCS cells leads to dose-dependent apoptosis and proliferation inhibition with the IC50 value being 32.3μM.  In conclusion, this study not only provides new insights into the mechanism of emodepside-induced vision blur but also offers a valuable molecular tool for the research of MCM6-CDT1 interaction."

Journal • CDT1 • MCM6

21 - New Drugs for Treatment of Filarial Infections (ASTMH 2025) - "The drugs presented during the symposium (Corallopyronin A, Oxfendazole, Emodepside, Moxidectin and a re-purposed antibiotic, fusidic acid) are in various stages of development, from transition between preclinical development and Phase I to Phase II or Phase III clinical trials. An initial clinical trial using Moxidectin in combination with Albendazole alone or with Albendazole and Diethylcarbamazine for treatment of lymphatic filariasis has been carried out to evaluate the efficacy of the different combinations. Moxidectin, with its confirmed efficacy for the treatment of onchocerciasis has been used for the first time for mass drug administration in Ghana.#Vaccinology#ChildHealth#InfectiousDisease#Prevention#NewDrugs#ClinicalTrials"

Infectious Disease

TREMO-Pemba: Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections (clinicaltrials.gov) - P3 | N=315 | Not yet recruiting | Sponsor: Swiss Tropical & Public Health Institute | Trial completion date: Nov 2025 ➔ Apr 2026 | Initiation date: May 2025 ➔ Oct 2025 | Trial primary completion date: Sep 2025 ➔ Feb 2026

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease

TREMO-Siargao: Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections (clinicaltrials.gov) - P3 | N=315 | Not yet recruiting | Sponsor: Swiss Tropical & Public Health Institute | Trial completion date: Feb 2026 ➔ Sep 2026 | Initiation date: Aug 2025 ➔ Jan 2026 | Trial primary completion date: Dec 2025 ➔ Jun 2026

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease

Positive allosteric modulation of emodepside sensitive Brugia malayi SLO-1F and Onchocerca volvulus SLO-1A potassium channels by GoSlo-SR-5-69. (PubMed, PLoS Pathog) - "In contrast, GoSlo-SR-5-69 binds at the RCK1 pocket. This study reveals for the first time, allosteric modulation of filarial nematode SLO-1 K channels by a mammalian BK channel activator and highlights its ability to increase emodepside potency on the B. malayi SLO-1 K channel."

Journal • Infectious Disease

Effects of Emodepside on Single-Channel Properties of Onchocerca volvulus SLO-1A (BK) Potassium Channels. (PubMed, Res Sq) - " This study successfully expressed Ovo -SLO-1A in HEK 293 cells, measured the conductance of the main open-state and detected the presence of sub-conductance states, and flickering openings. The increased amplitudes of the single-channel currents, open-burst times and open probabilities provide insights into how emodepside increases Slo-1K currents and illustrate dynamic actions of emodepside on Ovo -SLO-1A."

Journal • Infectious Disease • Ophthalmology

Emodepside for strongyloidiasis: insights from parasite genetics. (PubMed, Lancet Infect Dis) - No abstract available

Journal